Gilead Sciences' (GILD) Antiviral Drug Remdesivir Flops in First trial - FT

(Updated - April 23, 2020 12:55 PM EDT)

Gilead Sciences (NASDAQ: GILD) potential antiviral drug for coronavirus, Remdesivir, "flopped" in its first randomized clinical trial, according to the Financial Times, citing draft documents published accidentally by the WHO. The Chinese trial showed Remdesivir didn't improve patients' conditions or reduce the virus in the bloodstream. The drug also show significant side effects.

The study was terminated early due to low enrollment and was underpowered to enable statistical meaningful conclusions, said Gilead.

You May Also Be Interested In

• Gilead Sciences (GILD) Reiterated at Overweight by Cantor Fitzgerald: Yeztugo Total TRx Down
• FDA aligns with Regenxbio on path to refile MPS II gene therapy BLA
• FDA grants RMAT designation to Prime Medicine's CGD therapy PM359